Relay Therapeutics, Inc. (RLAY) Earnings Signals & AI Vibe Check
Cross-checked across multiple AI analysts and grounded in the latest SEC filing.
powered by: earningsVibe.ai
Question:
What is the latest filing signal for Relay Therapeutics, Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest
10-K, Relay Therapeutics, Inc.'s filing signal
turned positive.
earningsVibe SuperAnalyst™ Verdict:
TURNED POSITIVE
Signal Performance — Stock Price Since Filing
30-Day Change
+2.07%
from filing date
60-Day Change
Pending
from filing date
Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT
PERPLEXITY
Continuing Negative
GEMINI
Turned Positive
CLAUDE
Turned Positive
CHATGPT
Continuing Positive
Unlock the Full Filing Analysis
See full earningsSig™ and risksSig™ analysis across 5,000+ companies
Get Started Free →No credit card required
Question:
What does Relay Therapeutics, Inc. actually do?
Answer:
Relay Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for cancer and genetic diseases. The company leverages its proprietary Dynamo(R) platform, which integrates computational and experimental approaches to target proteins previously considered intractable. Its lead product candidate, zovegalisib, an allosteric PI3Kα inhibitor, is in Phase 3 development for breast cancer and is also being evaluated for vascular anomalies. Relay Therapeutics aims to advance its pipeline by focusing on genetically validated targets and selectively pursuing strategic partnerships.
Question:
What are Relay Therapeutics, Inc.'s revenue drivers?
Answer:
Revenue is primarily driven by upfront payments, milestone payments, and royalties from licensing and collaboration agreements, such as the Elevar Agreement for lirafugratinib and previously the Genentech Agreement for migoprotafib.
Cut through noisy SEC filings to find the signal faster
Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.
Get Started Free →No credit card required